Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are
recruited into the tumor site to fight against tumors. However, their small number and …

Breast cancer (BC), one of the most widespread and devastating diseases affecting women
worldwide, presents a significant public health challenge. This review explores the emerging …

Combination of different therapies is an attractive approach for cancer therapy. However, it is
a challenge to synchronize different therapies for maximization of therapeutic effects. In this …

The HER2-positive patients occupy~ 30% of the total breast cancer patients globally where
no prevalent drugs are available to mitigate the frequent metastasis clinically except …

Breast cancer (BC) is a malignant neoplasm that begins in the breast tissue. After skin
cancer, BC is the second most common type of cancer in women. At the end of 2040, the …

Gastric cancer (GC) is a severe malignancy, accounting for the third most common cancer
death worldwide. Despite the development of chemo-radiation therapy, there has not been …

New evidence suggests that the clinical success of chemotherapy is not merely due to tumor
cell toxicity but also arises from the restoration of immunosurveillance, which has been …

A robust understanding of the tumor immune environment has important implications for
cancer diagnosis, prognosis, research, and immunotherapy. Traditionally …

The role of inflammation in cancer is a topic that has been investigated for many years. As
established, inflammation emerges as a defining characteristic of cancer, presenting itself as …

Colorectal cancer (CRC) is the second leading cause of cancer death in the world.
Immunotherapy using monoclonal antibodies, immune-checkpoint inhibitors, adoptive cell …